Detection of erythropoiesis stimulating agent Luspatercept after administration to healthy volunteers for antidoping purposes

Luspatercept (Reblozyl®) is a newly approved anti‐anemic drug prohibited by the World Anti‐Doping Agency. It promotes erythropoiesis by limiting apoptosis of immature erythroblasts and the risk of misuse by athletes for doping is high. Proposed detection methods have been published recently but only...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchand, Alexandre, Miller, Geoff, Martin, Laurent, Gobbo, Coralie, Crouch, Andre K., Eichner, Daniel, Ericsson, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Special Issue ‐ Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084338/
https://www.ncbi.nlm.nih.gov/pubmed/35789123
http://dx.doi.org/10.1002/dta.3341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10084338/
https://www.ncbi.nlm.nih.gov/pubmed/35789123
http://dx.doi.org/10.1002/dta.3341

Ejemplares similares